|1.||Xu, Qin: 4 articles (06/2005 - 11/2002)|
|2.||Devidas, Meenakshi: 3 articles (07/2014 - 02/2006)|
|3.||Chen, Wan-tao: 3 articles (06/2005 - 11/2003)|
|4.||Guo, Wei: 3 articles (05/2004 - 11/2002)|
|5.||Tian, Xuan: 2 articles (01/2015 - 01/2009)|
|6.||Chauvenet, Allen: 2 articles (07/2014 - 02/2006)|
|7.||Steinbach, Joachim P: 2 articles (06/2014 - 09/2002)|
|8.||He, Jin: 2 articles (04/2014 - 08/2009)|
|9.||Ma, Li: 2 articles (06/2013 - 02/2013)|
|10.||Jiang, Shijun: 2 articles (06/2013 - 02/2013)|
01/01/1976 - "Out of six, VM 26 proved to be the most potent against tumor cells along with a moderate cytotoxicity against normal brain or embryonnic human cells. "
02/28/2013 - "The pharmacokinetic results indicated that the AUC(0-t) value of TSN in rats was significantly improved 5.41-fold than that of teniposide solution, moreover, the teniposide concentration in tumor from TSN was obviously improved over 7-fold in tumor bearing mice. "
01/01/2012 - "Both the clastogenic and the aneugenic potential of teniposide can give rise to the development of secondary tumours and abnormal reproductive outcomes in cured cancer patients and medical personnel exposing to drug regimens that include teniposide. "
04/01/1992 - "In this phase I study, teniposide was administered orally for 20 consecutive days to patients with refractory cancers. "
05/01/1990 - "This study indicates that teniposide has some, although limited, activity in cervical cancer."
|2.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/1992 - "The present study evaluated the clearance and pharmacodynamics of total and unbound teniposide in patients with acute lymphocytic leukemia who were either in first complete remission or who had relapsed and achieved a subsequent complete remission. "
04/01/1992 - "Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia."
04/01/2011 - "Our teniposide-resistant human lymphoblastic leukemia CEM cells (CEM/VM-1-5) express reduced Top2α protein compared with parental CEM cells. "
11/13/1992 - "Teniposide for acute lymphoblastic leukemia."
01/01/1992 - "Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia."
|3.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
03/01/1998 - "Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group."
09/15/1997 - "When administered according to the dosage and schedule selected for this study (60 mg/m2 i.v. on Days 1-5 every 3 weeks), teniposide as a single agent had modest activity in extensive small cell lung carcinoma. "
09/15/1997 - "Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group."
11/01/1988 - "Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC)."
06/01/1986 - "There have been few phase II studies of VM26 in patients with small cell lung cancer (SCLC). "
05/01/1990 - "Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy."
10/01/1986 - "Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group."
08/01/1986 - "We have characterized four lung carcinoma-derived cell lines for natural sensitivity or resistance to VP16-213 and VM26. "
01/01/1979 - "Use of VM-26 as a single agent in the treatment of renal carcinoma."
09/01/1986 - "In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay."
01/01/2008 - "Efficacy of radiochemotherapy of malignantly-converted brain gliomas using teniposide was evaluated in a randomized prospective study. "
04/01/1992 - "While many studies indicate that teniposide has significant potential in treatment of adult glioma, controlled trials are needed to evaluate and optimize the use of this agent."
02/01/1981 - "VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: preliminary report."
01/01/2014 - "Our findings not only reveal the novel mechanism involved in teniposide resistance, but also shed light on the optimization of glioma treatment in the future."
01/01/2014 - "It confers glioma cell sensitivity to teniposide through binding to the 3'-UTR region of MDM2 leading to its reduced expression. "
|1.||Teniposide (VM 26)
|8.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|5.||Heterologous Transplantation (Xenotransplantation)